Hyperfine (HYPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, will be held virtually to enhance participation and reduce costs and environmental impact.
Focus remains on expanding global access to portable, AI-powered MRI systems, with recent regulatory clearances in the US, Europe, and India.
Strategic priorities include broader adoption of the Swoop® system, continued innovation, and commercial expansion across multiple care sites and geographies.
Forward-looking statements highlight ongoing product development, commercial plans, and risk factors as outlined in the latest 10-K.
Voting matters and shareholder proposals
Shareholders will vote to elect five directors for one-year terms and to ratify Grant Thornton LLP as the independent auditor for fiscal 2026.
Board recommends voting in favor of all nominees and the auditor ratification.
Voting rights: Class A shares have one vote each; Class B shares have twenty votes each.
Dr. Rothberg, as the sole holder of Class B shares, controls a majority of voting power.
Board of directors and corporate governance
Board consists of five members, with three deemed independent under Nasdaq rules.
Board committees include audit, compensation, nominating and corporate governance, and a newly formed strategy committee.
Controlled company exemption applies due to Dr. Rothberg’s majority voting power, allowing exemptions from certain Nasdaq governance requirements.
Board leadership structure separates the roles of chairperson and CEO.
Corporate governance guidelines and codes of conduct are in place and publicly available.
Latest events from Hyperfine
- Vote on five director nominees and auditor ratification at the May 2026 virtual meeting.HYPR
Proxy filing14 Apr 2026 - Q4 2025 revenue up 128% year-over-year; 2026 guidance targets 55% growth and margin gains.HYPR
Q4 202519 Mar 2026 - Record Q2 revenue, raised 2024 guidance, and global expansion signal accelerating growth.HYPR
Q2 20242 Feb 2026 - Portable AI-powered brain MRI drives growth and expands access in neurology care.HYPR
Jefferies Global Healthcare Conference1 Feb 2026 - Portable brain MRI drives clinical and financial growth, targeting stroke and Alzheimer's markets.HYPR
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - AI-powered portable MRI drives growth, access, and efficiency in brain imaging markets.HYPR
Investor presentation20 Jan 2026 - Q3 revenue up 56% with record margins; global expansion and AI innovation fuel growth.HYPR
Q3 202414 Jan 2026 - 2024 revenue up 17%, margins improved, and 2025 guidance targets 20–30% growth.HYPR
Q4 202426 Dec 2025 - AI-powered portable brain MRI drives rapid growth and global expansion, with strong Q3 results.HYPR
Piper Sandler 37th Annual Healthcare Conference7 Dec 2025